Does metformin treatment during pregnancy modify future metabolic profile in women with PCOS?

Related Articles

Does metformin treatment during pregnancy modify future metabolic profile in women with PCOS?

J Clin Endocrinol Metab. 2018 Apr 05;:

Authors: Underdal MO, Stridsklev S, Oppen IH, Høgetveit K, Andersen MS, Vanky E

Abstract
Context: Worldwide, metformin is prescribed in an attempt to improve pregnancy outcome in PCOS. Metformin may also benefit future health by modulating the increased metabolic stress during pregnancy.
Objective: To investigate if metformin during pregnancy modified future metabolic health in women with PCOS.
Design: Follow-up study of a randomized controlled trial, which compared metformin to placebo in women with PCOS. Mean follow-up period was 8 years (5-11).
Setting: Three university hospitals, seven local hospitals, and one gynecological specialist practice.
Participants: Women with PCOS according to Rotterdam criteria, all former participants in the PregMet study.
Intervention: Metformin 2000 mg daily or placebo from 1st trimester to delivery in the original study. No intervention in the present follow-up study.
Main outcomes and measures: Main outcome measure was weight-gain in the follow-up period. Weight, body mass index, waist and hip circumferences and blood pressure were registered. Body composition was assessed by bioelectrical impedance analysis, and fasting lipids, glucose and insulin were analysed.
Results: 131 out of 239 (55%) invited women participated in the follow-up. Weight gain was similar in women given metformin (2.1±10.5) and women given placebo (1.8±11.2) at 7.7 years follow-up after pregnancy (p-value=0.834). No difference was found between those treated with metformin and placebo during pregnancy in BMI, waist/hip ratio, blood pressure, body composition, lipids, glucose and insulin levels or prevalence of metabolic syndrome at follow-up.
Conclusion: Metformin treatment during pregnancy did not influence the metabolic profile in women with PCOS at 7.7 years of follow-up.

PMID: 29659896 [PubMed - as supplied by publisher]

https://ift.tt/2HHwVVI